Given the density of single nucleotide polymorphisms (SNPs) in the human genome and the sensitivity of single nucleotide changes in microRNA (miRNA) functionality and processing, we asked whether polymorphisms within miRNA processing pathways and binding sites may influence non-small cell lung cancer (NSCLC) patients' prognosis. We These results indicate that miRNA-related polymorphisms may be associated with NSCLC patients' clinical outcomes through altered miRNA regulation of target genes.
INTRODUCTION
Lung cancer is the leading cause of cancer related mortality in the US (1) . Most early stage non-small cell lung cancer (NSCLC) patients are treated with curative-intent therapy. However, 50% of surgically resected patients will relapse within 5 years. Thus, there is a strong need to identify reliable prognostic and predictive biomarkers to assist in developing personalized therapy and follow-up care. Germline polymorphisms are characterized by their stability and accessibility. They have been identified as potential prognostic/predictive markers for NSCLC clinical outcomes and treatment response (2) .
MicroRNAs (miRNAs) are a class of small non-coding RNAs approximately 22 nucleotides in length. Emerging evidence has shown that miRNAs function as oncogenes or tumor suppressor genes depending on the context (3) (4) (5) and have been shown to be potential biomarkers for cancer risk assessment, treatment response, and prognosis (6) . MiRNAs undergo a complex processing procedure to produce the mature, functional unit (7) , and impaired miRNA processing has been reported to reduce stable miRNA levels and promote tumorigenesis (8) . Genetic variations in several miRNA processing genes have been reported to influence risk of several cancers (9) (10) (11) (12) . In addition, variations in miRNA binding sites within 3' untranslated regions (3'UTR) of target genes have been found to contribute to different outcomes in cancer patients (13) (14) (15) which could be a result of altered miRNA-mRNA interactions followed by changes in target gene expression (14) . For example, Zhang et al found that the G allele of rs1044129 in the miR-367 binding site of RYR3 was related to poor survival in 1, 125 breast cancer patients (16) NSCLC patients (13) .
In this study, we performed an analysis of 77 SNPs in eight miRNA processing genes and 163 SNPs in predicted miRNA binding sites for 133 cancer-related genes. We evaluated associations between these variants with overall survival and time to recurrence in early stage (I and II) NSCLC patients treated with curative therapy and also in subgroups of patients who received surgery-only or surgery plus chemotherapy.
We also performed luciferase reporter assays to determine the effect of selected binding site SNPs on gene regulation. 
MATERIALS AND METHODS

Study population and data collection
All the subjects included in the analysis were histologically confirmed NSCLC patients recruited at MD Anderson Cancer Center from September 1995 to February 2008, which is part of an ongoing lung cancer study initiated in 1991. Among all potential participants approached, 75% consented and were enrolled into the study (17) .
Blood samples were drawn from each participant. We restricted to early stage patients (stage I and II) who received curative-intent therapy (i.e. surgical resection, chemotherapy, and/or radiation therapy). The last day of follow-up for this study was 10,000 SNPs from 998 cancer-related genes. The details for the design of this chip, including the SNP and gene selection, were described previously, duplicates were included for 2% of all samples; the concordance rates were greater than 99% (18) .
Eight miRNA processing genes (DDX20, DGCR8, DICER1, DROSHA, EIF2C1, GEMIN4, RAN, and XPO5) were among the genes on this chip with 77 tagging (10 kb flanking and within each gene, linkage disequilibrium r 2 >0.8) and potential functional SNPs genotyped. We used the PolymiRTS v1.0 database to identify SNPs in predicted miRNA binding sites (all the 3'-UTR SNPs located within the seed region of responding miRNAs) (19) for the genes included on the chip and identified a total of 163 SNPs from 133 genes. These SNPs were selected to test the hypothesis that miRNA related genetic variations could influence NSCLC patients' clinical outcomes. All of the selected SNPs had a minor allele frequency greater than 0.01 in the Caucasian population.
Genomic DNA was extracted from peripheral blood samples using the QIAamp DNA extraction kit (Qiagen, Valencia, CA). Only SNPs with sample call rate > 95% and samples with SNP call rate >95% were included in the analysis.
Luciferase reporter assay
Luciferase reporter constructs for wildtype and variant binding site regions for 
Statistical analysis
Cox proportional hazard modeling was used to assess the association of SNPs with overall survival (the time between recruitment and death or last follow-up) and using the STREE program (20) to build a decision tree using recursive partitioning method. Briefly, the root node contained all the patients, and we defined the measure for goodness of split using log rank P value to select the optimal initial split and subsequent splits of the dataset until no statistically significant split was identified (20) .
All test were two-sided and associations with P value<0.05 considered significant.
Multiple hypothesis testing was performed using the "q-value" package in R (21) based on a false discovery rate (FDR) of 10%. Since 240 SNPs were tested for three models in each outcome analysis, therefore the P value was adjusted for multiple comparisons based on 720 tests. Bootstrap re-sampling was done for 500 iterations. In each resampling run, sampling with replacements was used to obtain same number of patients as the original analysis. 
RESULTS
Characteristics of patients
This study included 535 early stage NSCLC patients with an overall median survival time (MST) of 90.2 months and median follow-up time of 62.1 months. At the time of analysis, 213 (40%) of the patients had died and 133 (33%) had a recurrence of their disease. The majority of the NSCLC cases were adenocarcinomas (59%). Of the 535 participants, 340 patients received surgery-only, 127 patients were treated with surgery plus neoadjuvant and/or adjuvant chemotherapy, and the remaining was treated with radiation therapy with/without surgery ( Table 1) . 
Associations between individual SNPs and NSCLC clinical outcomes
Effects of treatments on association of clinical outcomes
We performed subgroup analysis focusing on two groups of patients: surgery-only and surgery plus chemotherapy.
Effect on overall survival
Eighteen SNPs were significantly associated with overall survival in surgery-only patients (Supplementary Table 1 
have opposite effects in both subgroups (Supplementary Table 2 ). For example, in patients receiving surgery plus chemotherapy, RRM2B:rs5005121 was associated with significantly increased risk of recurrence and a shortened MFST, but in surgery-only patients, this SNP was associated with decreased risk for recurrence with an increased MFST (P for interaction=0.015, q=0.170, Figure 2c and 2d) , however, the interaction between this SNP with treatments was not significant after multiple comparison corrections. Figure 3 shows the survival-tree structure classifying patients into subgroups with distinct risk of dying based on their risk genotype combinations. SNPs that displayed at least borderline significant association with survival in the main effect analysis after multiple comparisons (q<0.15) were included in the analysis, and none of these SNPs were in high LD. The MSTs based on these groupings varied from > 86 months for the low risk group to 41.7 months for the high risk group in surgery-only patients, and from > 118 months to 36.8 months for the low and high risk groups, respectively in patients receiving surgery plus chemotherapy. Moreover, the initial splits in the tree structure for each subgroup, FZD4:rs713065 and FAS:2234978, were also the two SNPs that remained significant after multiple comparisons in the treatment subgroup analyses.
Survival tree analysis
Survival tree analysis was not performed for recurrence due to limited number of SNPs with q<0.15.
Bootstrap re-sampling analysis
Research. All the SNPs that were significant after multiple comparisons at an FDR of 5% remained significant in the bootstrap analysis for at least 450 out of 500 re-samplings, providing internal validation to these results. Bootstrap re-sampling analysis was also performed for survival tree analyses, and the results were significant in both the subgroups analysis for entire 500 re-samplings at P<0.05 (Supplementary Figure 1) .
The effect of selected miRNA binding site variants on miRNA-regulation
Luciferase reporter assays were performed to determine the effect of these predicted binding site variants on miRNA regulation of target genes. FAS:rs2234978, which was consistently associated with a favorable prognosis, was predicted to create a new miRNA binding site for miR-561. In two lung cancer cell lines, H460 and H2444, a significant reduction in luciferase activity was observed when miR-561 was transfected 
DISCUSSION
In this study, we identified genetic variants in miRNA processing genes and miRNA binding sites near cancer-related genes that were associated with overall survival and recurrence in early stage NSCLC patients. FAS:rs2234978 was identified as a potential prognostic factor in our results and functional data provided evidence that this SNP alters miRNA regulation of FAS. We also found evidence that some SNPs exhibited associations that were treatment-specific. These results suggest that genetic variants in miRNA processing genes and miRNA binding sites may serve as potential prognostic markers for survival and predictive markers of response to treatment.
The most significant SNP associated with survival was FAS:rs2234978, which was consistent regardless of treatment regimens. FAS is a cell-surface receptor of the tumor necrosis family which plays an important role in the regulation of apoptosis. Evidence has shown FAS expression and polymorphisms could influence lung cancer patients' prognosis (22, 23) . Rs2234978 is a synonymous SNP located in the seventh exon of SP1:rs17695156 is the most significant SNP associated with increased risk for death. SP1 is a transcription factor known to regulate expression of many genes, thus having a general regulatory role within the cell. This SNP is predicted to disrupt a conserved miRNA site; however, in our in vitro experiments, we did not observe any significant difference between the two alleles in miRNA-induced repression of reporter activity. It is possible that this 3'UTR SNP might affect SP1 expression independent of its putative role as a miRNA target site (e.g. affecting RNA stability or post-transcriptional regulation) and influence cellular components at physiological levels. And it is also possible that 
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